Class / Patent application number | Description | Number of patent applications / Date published |
514327000 | Chalcogen bonded directly to ring carbon of the piperidine ring | 62 |
20080300280 | Cyanobenzene Compounds for Combating Animal Pests - The present invention relates to a method of combating animal pests which comprises contacting the animal pests, their habit, breeding ground, food supply, plant, seed, soil, area, material or environment in which the animal pests are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from animal attack or infestation with a pesticidally effective amount of at least one cyanobenzene compound of the formula (I) and/or at least one agriculturally acceptable salt thereof: where m is 0, 1 or 2; is a radical of the formulae N═CR | 12-04-2008 |
20080312283 | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts - Methods to prevent, inhibit, or slow the development of vitrectomy-induced cataracts are disclosed. The methods comprise administering to the eye of a subject a composition comprising an opthalmologically acceptable carrier or diluent and at least one hydroxylamine compound in a therapeutically sufficient amount to prevent, inhibit, or slow the development of a vitrectomy-induced cataract in the subject to which the composition is administered. | 12-18-2008 |
20090042942 | Muscarinic Receptor Antagonists - The invention provides compounds of formula (I), wherein R | 02-12-2009 |
20090176833 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY - This invention relates to compounds of formula I: | 07-09-2009 |
20090247584 | PHENOXY-PIPERIDINES FOR THE TREATMENT OF DISEASES SUCH AS SCHIZOPHRENIA AND DEPRESSION - Compounds of the formula (I), in which R | 10-01-2009 |
20090326010 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes the compound of formula (I): | 12-31-2009 |
20100004289 | SUBSTITUTED BUTYROPHENONE DERIVATIVES - The present invention relates to a central nervous system-acting substituted butyrophenones. These compounds are useful in antipsychotic medications for psychosis, including schizophrenia, but especially for L-DOPA-induced psychosis, while having low or no risk of eliciting extrapyramidal side effects, hyperprolactinemia or tardive dyskinesia. | 01-07-2010 |
20100016366 | Novel Compounds Active as Muscarinic Receptor Antagonists - The invention relates to compounds of formula | 01-21-2010 |
20100029720 | Carboxamide Derivatives As Muscarinic Receptor Antagonists - The invention relates to compounds of formula | 02-04-2010 |
20100063096 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 03-11-2010 |
20100105736 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES - A compound having the general formula | 04-29-2010 |
20100168170 | Piperidinones Useful in the Treatment of Inflammation - There is provided compounds of formula (I), wherein R | 07-01-2010 |
20100168171 | Piperidinone Carboxamide Derivatives as P2X7 Modulators - The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 07-01-2010 |
20100240703 | OXYIMINO COMPOUNDS AND THE USE THEREOF - The invention relates to oxyimino compounds of (Formula I), and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SO | 09-23-2010 |
20100298382 | COMPOSITIONS AND METHODS FOR ALLEVIATING DEPRESSION OR IMPROVING COGNITION - This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition. | 11-25-2010 |
20100305159 | CRYSTALLINE FORM OF PIPERIDINE COMPOUND - The present invention is to provide a crystalline form of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine or a solvate thereof. | 12-02-2010 |
20110021569 | Piperidine compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 01-27-2011 |
20110053984 | NOVEL 4-BENZHYDRYLOXY-TETRAALKYL-PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel 4-benzhydryloxy-tetraalkyl-piperidine derivatives of Formula (I), any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R | 03-03-2011 |
20110086881 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND - The invention relates to crystalline free base forms of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also relates to pharmaceutical compositions containing or prepared from such crystalline forms; processes and intermediates useful for preparing such crystalline forms; and methods of using such crystalline forms to, for example, treat a pulmonary disorder. | 04-14-2011 |
20110105563 | IL-8 RECEPTOR ANTAGONISTS - This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). | 05-05-2011 |
20110190350 | PHOSPHODIESESTERASE 4 INHIBITORS FOR THE TREATMENT OF A COGNITIVE DEFICIT - The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors. | 08-04-2011 |
20110257229 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES - Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. | 10-20-2011 |
20120004266 | DOPAMINE-BETA-HYDROXYLASE GENETIC POLYMORPHISM AND MIGRAINE - The invention provides a method of determining whether or not an individual has a predisposition to migraine including the step of determining whether an isolated nucleic acid obtained from the individual comprises a nucleotide sequence corresponding to at least a fragment of a dopamine β-hydroxylase (DBH) gene promoter, wherein the presence of a −1021C→T single nucleotide polymorphism (SNP) in said nucleotide sequence indicates whether or not said individual has an increased predisposition to migraine compared to an individual without the polymorphism. DBH −1021C/C homozygotes are particularly susceptible to migraine. The −1021T allele may exert a protective effect. The method is particularly suited to detection of a predisposition to migraine with aura in females. The invention also provides a diagnostic kit for detecting a −1021C→T SNP associated with migraine. The method and kit may facilitate selection of individuals for migraine therapy which targets the dopaminergic system. | 01-05-2012 |
20120029021 | Nitroxide Free Radical Synergized Antineoplastic Agents - Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the products formed from the adducts after administration. | 02-02-2012 |
20120115910 | COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE - This application describes compositions of receptor inhibitors, including typical antipsychotic agents, for example haloperidol, and methods of use for treating clinical signs or symptoms of Parkinson's disease. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in Parkinson's disease as a means of alleviating the clinical signs or symptoms of Parkinson's disease. | 05-10-2012 |
20120196898 | PHOSPHODIESTERASE 4 INHIBITORS FOR COGNITIVE AND MOTOR REHABILITATION - The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance. | 08-02-2012 |
20120283293 | Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation - The present invention provides methods for attenuating neuronal inflammation and neuronal damage in case of acute or chronic injury of nerve cells of the central nervous system through prostaglandin E2 EP4 receptor activation. Methods for treating neuropathic pain are also provided. | 11-08-2012 |
20130023564 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes the compound of formula (I): | 01-24-2013 |
20130079370 | Method for the Inhibition of Deubiquitinating Activity - A method of treating in a person a cancer tumor refractory to treatment with bortezomib or an agent sharing the apoptosis generating activity of bortezomib or any other anti-cancer drug, comprises administering to the person, in a pharmaceutically acceptable carrier, a pharmacologically effective dose of an agent selected from the group consisting of b-AP15 and other proteasome inhibitor abrogating the deubiquitinating (DUB) activity of the 19S RP DUBs. | 03-28-2013 |
20130143924 | COMPOSITION FOR REPELLING AND DETERRING VERMIN - The present invention is directed to a non-therapeutical process for deterring vermin, which is based on the usage of the largely known beta amino-alcohol derivatives of formula (I) | 06-06-2013 |
20130203815 | CYTOKINE INHIBITORS - The present invention provides compounds represented by general formula (I): | 08-08-2013 |
20130245068 | COMPOSITION COMPRISING BENPROPERINE DERIVATIVES AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING ANGIOGENESIS-RELATED DISEASES - The present invention relates to a novel pharmaceutical composition of benproperine derivatives for preventing and treating angiogenesis-related diseases. The benproperine derivatives and pharmaceutically acceptable salts thereof according to the present invention inhibit cancer cell migration and the angiogenesis of vascular endothelial cells, and therefore can be effectively used not only as an anticancer agent, but also as an agent for preventing and treating diseases caused by abnormal angiogenesis, such as diabetic retinopathy and corneal transplant rejection. | 09-19-2013 |
20130296367 | COMPOSITIONS AND METHODS FOR ALLEVIATING DEPRESSION OR IMPROVING COGNITION - This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition. | 11-07-2013 |
20140163071 | BIOAVAILABLE COMPOSITIONS OF AMORPHOUS PIPERIDINYL COMPOUNDS - This invention relates to solid amorphous dispersions comprising Compound I having the formula (formula I), or stereoisomers thereof, and one or more polymers. More particularly, this invention relates to bioavailable amorphous solid dispersions of Compound I that are unexpectedly stable in suspension and in the solid state for extended periods of time that may be used for tabletting. | 06-12-2014 |
20140243372 | BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER - The present invention provides a MDM2 inhibitor compound, or a pharmaceutically acceptable salt thereof, which compound is useful as a therapeutic agent, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contains the MDM2 inhibitor. | 08-28-2014 |
20140249184 | POLYMER-BASED SURGICALLY IMPLATABLE HALOPERIDOL DELIVERY SYSTEMS AND METHODS FOR THEIR PRODUCTION AND USE - Surgically implantable drug delivery systems for long-term delivery of haloperidol containing a biodegradable polymer and haloperidol fabricated into the surgically implantable drug delivery systems via solvent casting and compression molding are provided. Also provided are methods for producing the surgically implantable drug delivery systems and methods for using these systems in the treatment of psychotic disorders such as schizophrenia. | 09-04-2014 |
20140364455 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR - The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates. | 12-11-2014 |
20140371270 | NOVEL ACETIC ACID ESTER COMPOUND OR SALT THEREOF - An acetic acid ester compound represented by the following formula (I) or a salt thereof, | 12-18-2014 |
20150099786 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS - The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. | 04-09-2015 |
20150119422 | SIMETHICONE FORMULATION - The present invention relates to solid pharmaceutical formulations based on simethicone and calcium phosphate and mannitol. | 04-30-2015 |
20150126554 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION - Methods of preventing and treating gastrointestinal dysfunction, particularly postoperative ileus and post-partum ileus, in a patient undergoing surgery or other biological stress by administering 4-aryl-piperidine derivatives are disclosed. | 05-07-2015 |
20150320735 | METHOD FOR TREATING/PREVENTING DISEASE USING COGNITIVE ABILITY OF CEREBRUM AND PHARMACEUTICAL - An object of the present invention is to develop a method of enhancing the cognitive ability of a brain to fundamentally cure a disease. It has been found out that, by using a medicament for treating or preventing a disease including a combination of a major tranquilizer, and vitamin C or a salt thereof and, if necessary, drip infusion, an antidepressant and an iron agent, the cognitive ability of a brain is enhanced, thus, an arbitrary disease including various cancers can be treated. The present invention also provides a method for treating or preventing a disease including a step of administering a major tranquilizer, and vitamin C or a salt thereof to a subject suffering from the disease. | 11-12-2015 |
20160011201 | Method For Predicting Responsiveness To Compound Inhibiting MAPK Signal Transduction Pathway | 01-14-2016 |
20160039757 | PHENYL DERIVATIVE - An object of the present invention is to provide a compound having strong human S1P | 02-11-2016 |
20160115129 | NOVEL FLUORINATED BENZILIC ACID ESTER COMPOUND AND SALT THEREOF - A benzilic acid ester compound represented by the following formula (I) or a salt thereof, | 04-28-2016 |
20160168094 | PYRROLIDIN-2-ONE AND PIPERIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | 06-16-2016 |
20180021299 | PHOSPHODIESTERASE 4 INHIBITORS FOR COGNITIVE AND MOTOR REHABILITATION | 01-25-2018 |
514328000 | Plural chalcogens bonded directly to ring carbons of the piperidine ring | 15 |
20080221164 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use - Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity. | 09-11-2008 |
20080234324 | Piperidine Derivatives as Gcs Inhibitors - The present invention relates to novel piperidine derivatives that are useful as inhibitors of glucosylceramide synthase (GCS) for use in the treatment and prevention of diseases or disorders mediated by GCS, including cancer, infectious diseases, neuronal disorders or injury and inflammatory diseases. The invention further relates to the pharmaceutical composition comprising the novel piperidine derivatives and methods for preparing the same. | 09-25-2008 |
20080287500 | Diastereomers of 4-aryloxy-3-hydroxypiperidines - The present invention relates to essentially pure diastereomers of 4-aryloxy-3-hydroxypiperidines, including purified diastereomers of ifoxetine, methods of purifying said diastereomers, pharmaceutical compositions comprising said diastereomers and methods of treatment utilizing said pharmaceutical compositions. | 11-20-2008 |
20100317696 | IMINOSUGARS AND METHODS OF TREATING BUNYAVIRAL AND TOGAVIRAL DISEASES - Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives. | 12-16-2010 |
20110065752 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS - Provided are novel iminosugars and methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Orthomyxoviridae family using iminosugars, such as DNJ derivatives. | 03-17-2011 |
20110065753 | METHODS OF TREATING POXVIRAL INFECTIONS - Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Poxyiridae family using iminosugars, such as DNJ derivatives. | 03-17-2011 |
20110065754 | IMINOSUGARS AND METHODS OF TREATING FILOVIRAL DISEASES - Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Filoviridae family using iminosugars, such as DNJ derivatives. | 03-17-2011 |
20110092541 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM - The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease. | 04-21-2011 |
20120149733 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes the compound of formula (I): | 06-14-2012 |
20120220632 | Methods For Treatment of Fabry Disease - Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone. | 08-30-2012 |
20130237567 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES - Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars. | 09-12-2013 |
20140080871 | Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System - The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease. | 03-20-2014 |
20150299122 | GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 10-22-2015 |
20150335630 | Novel Alkylated Imino Sugars Exhibiting Glucosidase Inhibition and Their Method of Use - Pharmaceutical compositions of the invention comprise alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include Viral hemorrhagic fevers, and any other diseases involving glucosidase activity. | 11-26-2015 |
20160022643 | Oral Transmucosal Compositions including Aromatase Inhibitors for Low Testosterone Levels in Men - Formulations for oral transmucosal compositions that include aromatase inhibitors (AIs) in combination with transmucosal absorption enhancers are disclosed. Disclosed oral transmucosal compositions may be for immediate release or slow release, and may be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Disclosed oral transmucosal compositions may include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms may include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms may be: mucoadhesive liquids such as gel-forming liquid; gel-forming; semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of AIs. Disclosed oral transmucosal compositions may allow the delivery of AIs directly into the patient's bloodstream, thus providing high bioavailability of AIs; therefore, required dose may be lower. Additionally, adjustments of AIs dosages may be achieved when using disclosed oral transmucosal compositions. | 01-28-2016 |